ADispell will take a new patented discovery about the operation of signal receptors on brain neurons and new proprietary discoveries about toxicity from beta-amyloid plaque to advance lead drug compounds that have been identified by the company through development and clinical trial phases.

You have seen the size of the markets in which ADispell will be working. You know that the financial opportunities with blockbuster drugs are huge. ADispell has designed a development approach that offers a lucrative return on investment in three years or less. Or, if you desire, you can stay involved with the company for a longer time period and participate in the attractive returns from sales of product.